Page 162 - Haematologica - Vol. 105 n. 6 - June 2020

J.A. Cohen et al.
et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10):1640-1645.
18. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
19. Bulian P, Shanafelt TD, Fegan C, et al. CD49d is the strongest flow cytometry- based predictor of overall survival in chron- ic lymphocytic leukemia. J Clin Oncol. 2014;32(9):897-904.
20. Else M, Wade R, Oscier D, et al. The long- term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years. Br J Haematol. 2016;172(2):228-237.
21. Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010;95(10):1705-1712.
22. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 muta- tion analysis in chronic lymphocytic leukemia. Leukemia. 2012;26(7):1458-1461.
23. D'Agaro T, Bittolo T, Bravin V, et al. NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. Br J Haematol. 2018;182(4):597-602.
24. Pozzo F, Bittolo T, Arruga F, et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dys- regulation. Leukemia. 2015;30(1):182-189.
25. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121 (24):4902-4905.
26. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identi- fies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121 (8):1403-1412.
27. Malcikova J, Tausch E, Rossi D, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemi- aƒ_"update on methodological approaches and results interpretation. Leukemia. 2018;32(5):1070-1080.
28. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a compet- ing risk. J Am Stat Ass. 1999;94(446):496- 509.
29. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a
predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29(16):2223-2229.
30. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independ- ent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995-1004.
31. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated sub- clones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139-2147.
32. Molica S, Giannarelli D, Levato L, et al. A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treat- ment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL). Int J Hematol. 2014;100(3):290-295.
33. Bulian P, Tarnani M, Rossi D, et al. Multicentre validation of a prognostic index for overall survival in chronic lym- phocytic leukaemia. Hematol Oncol. 2011;29(2):91-99.
34. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115(2):363-372.
35. Shanafelt TD, Kay NE, Rabe KG, et al. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lym- phocytic lymphoma (SLL). Cancer. 2012;118(7):1827-1837.
36. Langerbeins P, Bahlo J, Rhein C, et al. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lym- phocytic leukemia patients with risk of early disease progression. Future Oncol. 2015;11(13):1895-1903.
37. Gerstung M, Papaemmanuil E, Martincorena I, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49(3):332-340.
38. Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379(15):1416-1430.
39. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lympho- cytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998;338(21):1506-1514.
40. Hoechstetter MA, Busch R, Eichhorst B, et al. Early, risk-adapted treatment with flu- darabine in Binet stage A chronic lympho-
cytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017;31(12):2833-2837.
41. Hallek M. On the architecture of transla- tional research designed to control chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2018;2018 (1):1-8.
42. Dal Bo M, Del Principe MI, Pozzo F, et al. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a ritux- imab-based induction and consolidation treatment. Ann Hematol. 2014;93(10): 1765-1774.
43. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational acti- vation. J Exp Med. 2011;208(7):1389-1401.
44. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refrac- toriness. Blood. 2011;118(26):6904-6908.
45. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with flu- darabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119(12):2854-2862.
46. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-336.
47. Rossi D, Gaidano G. Lymphocytosis and ibrutinib treatment of CLL. Blood. 2014;123(12):1772.
48. Del Giudice I, Mauro FR, De Propris MS, et al. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica. 2011;96(4):626.
49. Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent pre- dictor of overall survival in patients with chronic lymphocytic leukaemia: a prognos- tic parameter with therapeutic potential. Br J Haematol. 2008;140(5):537-546.
50. Rossi D, Zucchetto A, Rossi FM, et al. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica. 2008;93(10):1575-1579.
51. Zucchetto A, Caldana C, Benedetti D, et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evi- dence for a methylation-dependent regula- tion mechanism. Blood. 2013;122(19):3317- 3321.
1620
haematologica | 2020; 105(6)